Current states of prevention of drug-induced gastroduodenal ulcer in clinical real practice

**CURRENT STATUS:** POSTED

Junichi Iwamoto  
Tokyo medical university ibaraki medical center  
<i>iwamotoj@tokyo-med.ac.jp</i>  
Corresponding Author  
ORCiD: https://orcid.org/0000-0002-5238-3272

Tadakuni Monma  
Tokyo medical university ibaraki medical center

Hajime Ueda  
Tokyo Medical university ibaraki medical center

Makoto Tamamushi  
Tokyo medical university ibaraki medical center

Naoki Konishi  
Tokyo medical university ibaraki medical center

Shoichiro Yara  
Tokyo medical university ibaraki medical center

Masashi Murakami  
Tokyo medical university ibaraki medical center

Takeshi Hirayama  
Tokyo medical university ibaraki medical center

Akira Honda  
Tokyo medical university ibaraki medical center

Tadashi Ikegami  
Tokyo medical university ibaraki medical center

Yuji Mizokami  
University of Tsukuba
**DOI:**
10.21203/rs.2.11424/v1

**SUBJECT AREAS**
Gastroenterology & Hepatology

**KEYWORDS**
NSAIDs: Non-steroidal anti-inflammatory drugs, LDA: low-dose aspirin H2RA: histamine H2 receptor antagonist, PPI: proton pump inhibitor
Abstract
Background and Aim: Non-steroidal anti-inflammatory drugs (NSAIDs) or low-dose aspirin (LDA) are the most common causes of drug-induced gastroduodenal ulcer. We investigated preventive treatment with use of concomitant anti-ulcer drugs and the clinical features of gastroduodenal ulcer in cases treated with these drugs.

Method: A total of 2,332 patients with gastroduodenal ulcer and 241 patients with bleeding gastroduodenal ulcer were classified into 3 groups: those taking LDA, those taking non-aspirin NSAIDs (hereinafter referred to as NSAIDs), and those taking neither aspirin nor NSAIDs. Chronological changes in the percentage of each group and the change over the past 15 years were investigated. The status of prevention of ulcer and clinical features were examined in 264 patients with gastroduodenal ulcer taking NSAIDs or LDA, including 107 bleeding cases, in the past 8 years.

Results: From January 2002 to December 2017, the percentage of all patients taking LDA increased until 2013, but from 2014, the percentage of patients taking LDA decreased in those with a bleeding ulcer. The percentage of patients taking NSAIDs decreased from 2002 in those with a bleeding ulcer. Among the 264 patients with gastroduodenal ulcer and the 107 patients with a bleeding ulcer taking NSAIDs and LDA, 16 (6%) and 9 (8%), respectively, were receiving preventive treatment with concomitant anti-ulcer drugs. The percentages of patients taking LDA and other antiplatelet drugs in patients with bleeding gastroduodenal ulcer were significantly higher than those in patients with non-bleeding.

Conclusion: Although the percentages of patients with gastroduodenal ulcer taking NSAIDs or LDA have not recently increased in real-world practice, preventive treatment in these patients is still low. This low rate of prevention in cases of non-bleeding and bleeding gastroduodenal ulcer suggests the need to enlighten physicians about preventive treatment because drug withdrawal of LDA has a high risk of cardiovascular and cerebrovascular events

Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used for pain in rheumatoid arthritis or orthopedic disease and are the most common cause of drug-induced gastroduodenal ulcer\(^{1,2}\). LDA is
now commonly used for prevention of cardiovascular and cerebrovascular events with the advent of aging of society\textsuperscript{3-5}. Worldwide trials have shown that LDA at 75-325 mg/day or other antiplatelet regimens offers beneficial protection against myocardial infarction, stroke, and death\textsuperscript{4}. In contrast, a very low dose of aspirin (10 mg daily) decreases gastric mucosal prostaglandin levels and causes significant gastric mucosal damage\textsuperscript{6}, and this may have increased the incidence of LDA-induced gastrointestinal mucosal injury\textsuperscript{7-10}.

In cases of drug-induced gastroduodenal ulcer bleeding, drug withdrawal including LDA involves a high risk of cardiovascular and cerebrovascular events. Therefore, prevention of gastroduodenal ulcer bleeding in patients taking drugs including NSAIDs and LDA is clinically important\textsuperscript{11 12}, but it is unclear to what extent preventive treatment is being used in such cases in real world practice. Therefore, in the present study, we investigated chronological changes in use of NSAIDs and LDA in patients with gastroduodenal ulcer taking NSAIDs and LDA and examined the current status of prevention for these cases in clinical practice.

**Patients And Methods**

Among 41,802 patients who underwent gastrointestinal endoscopy between January 2002 and December 2017 (excluding cases with ulcer scar, stomal ulcer and severe complications), 2,332 patients with gastroduodenal ulcer (1,634 with gastric ulcer and 698 with duodenal ulcer; ratio 2.37:1), including 580 (446 with gastric ulcer and 134 with duodenal ulcer; ratio 3.32:1) with bleeding ulcer, were diagnosed at Tokyo Medical University Ibaraki Medical Center and included in the study. Informed consent was obtained from all subjects, and the experimental protocol was approved by the Ethics Committee of Tokyo Medical University Ibaraki Medical Center.

The 2,332 patients were classified into three groups: those taking LDA, those taking non-aspirin NSAIDs (hereinafter referred to as NSAIDs), and those taking neither LDA nor NSAIDs. Patients receiving a combination of LDA and NSAIDs were placed in the NSAIDs group. Chronological changes in the percentage of each group and the change in percentages over 15 years were investigated.

In a sub-analysis, among 768 patients with gastroduodenal ulcer (538 with gastric ulcer and 230 with
duodenal ulcer; ratio 2.34:1) of 18,225 patients who underwent gastrointestinal endoscopy in the 7 years from January 2011 to December 2017, we evaluated 264 patients with gastroduodenal ulcer (202 with gastric ulcer and 62 with duodenal ulcer) taking NSAIDs or LDA, including 107 with a bleeding ulcer. Use of preventive treatment with concomitant anti-ulcer drugs and clinical features of cases under preventive treatment were examined.

Statistical analysis
Data are expressed as mean ± SD. Categorical variables were compared by chi-square test, and continuous variables by Mann-Whitney test, with P < 0.05 considered to be significant.

Results
Chronological changes in patients with gastroduodenal ulcer taking NSAIDs and LDA
For the patients with all or bleeding gastroduodenal ulcer, the mean ages of those taking LDA and NSAIDs were higher than those taking neither LDA nor NSAIDs (p<0.05). In these patients, the male/female ratio in those taking NSAIDs was lower than those in the other groups (p<0.05) (Table 1). From January 2002 to December 2017, the percentage of all patients taking NSAIDs and LDA increased significantly until 2010 (p<0.05), but then started to decrease in 2011; and the percentage of all patients taking NSAIDs and LDA decreased significantly (p<0.05) until December 2017. In patients with a bleeding ulcer, use of LDA increased until 2013 and then started to decrease in 2014, but without significance; and the percentage of all patients taking NSAIDs and LDA decreased until December 2017, again with no significance (Figures 1 and 2).

Preventive treatment in patients with gastroduodenal ulcer taking NSAIDs and LDA
Among the 264 patients with gastroduodenal ulcer taking NSAIDs and LDA, 16 (6%) were receiving preventive treatment with concomitant anti-ulcer drugs, and 248 (94%) were not receiving this treatment. In the 107 patients with a bleeding ulcer taking NSAIDs and LDA, 9 (8%) were receiving preventive treatment, and 98 (92%) were not (Table 2). In the 16 cases receiving preventive treatment, 11 (69%) and 5 (31%) were taking a half dose and a full dose of a proton pump inhibitors (PPIs) (Table 3). In patients with non-bleeding and bleeding gastroduodenal ulcer, 85.7% and 22.2%
were taking a single NSAID, and 14.3% and 77.8% were taking LDA or another antiplatelet drug, respectively. The ratio of bleeding gastroduodenal ulcer taking LDA or another antiplatelet drug were higher than that of non-bleeding cases, significantly (Table 4).

**Discussion**

The efficacy of LDA for prevention of cardiovascular and cerebrovascular diseases has been established\(^3\)\(^4\)\(^5\), but the risks of peptic ulcer complications increase in association with LDA use \(^6\)\(^7\)\(^8\)\(^9\)\(^10\). A meta-analysis of 24 randomized controlled trials revealed that gastrointestinal hemorrhage occurred in 2.47% of patients taking aspirin compared with 1.42% taking placebo\(^7\).

We investigated the chronological changes in use of NSAIDs and LDA in patients with gastroduodenal ulcer since 2002. The percentage of these patients taking NSAIDs or LDA initially increased, but has decreased in recent years. High doses of histamine H2 receptor antagonist (H2RAs), PPIs or prostaglandin analogs are recommended for prevention of NSAID or LDA-induced gastroduodenal ulcer, and PPIs are especially used widely as first-line drugs\(^11\)\(^12\). The spread of preventive use of PPIs may have caused the chronological changes in use of LDA and NSAIDs found in the current study.

However, in real world practice in our hospital, only 6% of patients with gastroduodenal ulcer taking NSAIDs and LDA were receiving preventive treatment with concomitant anti-ulcer drugs over the last 8 years, which indicates that use of this treatment is still insufficient.

Prevention of ulcer using PPIs is recommended, but some previous reports have suggested that this treatment is insufficient\(^13\)\(^14\). For example, it has been reported that 13% of cases had recurrence of gastroduodenal ulcer after treatment with 15 mg lansoprazole\(^15\). In cases of LDA-induced gastroduodenal ulcer and bleeding, discontinuation of LDA can increase the risk of cardiovascular and cerebrovascular diseases\(^16\)\(^17\)\(^18\), and continuation of LDA is recommended\(^12\). Sung et al. investigated continuation of aspirin therapy with PPIs after endoscopic control of ulcer bleeding, and found that this was not inferior to stopping aspirin\(^18\). The results showed that patients who continued aspirin had lower all-cause mortality and lower mortality attributable to cardiovascular, cerebrovascular, or gastrointestinal complications, compared to patients who stopped aspirin\(^18\). Since stopping LDA after
Gastroduodenal bleeding increases the risk of cardiovascular and cerebrovascular diseases, more thorough preventive treatment is needed. Recently, the efficacy of vonoprazan for prevention of NSAID and LDA-induced gastroduodenal ulcer has been reported in Japan$^{19,20}$. In cases under treatment with concomitant anti-ulcer drugs, we found that a significant higher rate of use of single NSAIDs in non-bleeding cases than in bleeding cases, and we also found a significant higher rate of use of LDA or other antiplatelet drugs in bleeding cases. These results may indicate that, in contrast to patients taking LDA or other antiplatelet drugs, those taking a single NSAID have a lower risk of gastroduodenal bleeding while under preventive treatment. These results also suggest that greater attention to gastroduodenal bleeding is needed in patients taking LDA or other antiplatelet drugs with concomitant preventive therapy.

In conclusion, although preventive treatment with PPIs is recommended, we found that this treatment is insufficiently applied in real world practice, and that few patients with gastroduodenal ulcer are receiving concomitant anti-ulcer drugs. However, stopping LDA after gastroduodenal bleeding increases the risk of cardiovascular and cerebrovascular diseases, and therefore, more thorough preventive treatment is needed in these cases.

Declarations

Acknowledgements

I received generous support from Professor Yasushi Matsuzaki.

Data Availability

All data generated or analyzed during this study are included in this article.

Conflicts of interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

References

1. Larkai EN, Smith JL, Lidsky MD, et al. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 1987;82:1153-8.
2. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987;28:527-32.
3. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after
cerebrovascular ischaemic events. The SALT Collaborative Group. Lancet 1991;338:1345-9.

4. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106.

5. Lauer MS. Clinical practice. Aspirin for primary prevention of coronary events. N Engl J Med 2002;346:1468-74.

6. Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999;117:17-25.

7. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000;321:1183-7.

8. Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin 2007;23:163-73.

9. Sorensen HT, Mellemkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000;95:2218-24.

10. Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005;22:795-801.

11. Gargallo Cj, Sostres C, Lanas A. Prevention and Treatment of NSAID Gastropathy. Curr Treat Options Gastroenterol 2014;12:398-413.

12. Satoh K, Yoshino J, Akamatsu T, et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2015. J Gastroenterol 2016;51:177-94.

13. Sugano K, Matsumoto Y, Itabashi T, et al. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol 2011;46:724-35.

14. Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol
15. Sugano K, Kontani T, Katsuo S, et al. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol 2012;47:540-52.

16. Ferrari E, Benhamou M, Cerboni P, et al. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 2005;45:456-9.

17. Maulaz AB, Bezerra DC, Michel P, et al. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol 2005;62:1217-20.

18. Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010;152:1-9.

19. Mizokami Y, Oda K, Funao N, et al. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut 2018;67:1042-1051.

20. Kawai T, Oda K, Funao N, et al. Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study. Gut 2018;67:1033-1041.

Tables
Due to technical limitations, tables 1 through 4 are only available as a download in the supplemental files section.

Figures
Figure 1. Chronological changes in use of NSAIDs and LDA in all patients with gastroduodenal ulcer.

*p < 0.05 and **p < 0.05 for comparison between each patient group.

Chronological changes in use of NSAIDs and LDA in all patients with gastroduodenal ulcer.

*p < 0.05 and **p < 0.05 for comparison between each patient group.
Figure 2. Chronological changes in use of NSAIDs and LDA in patients with bleeding due to gastroduodenal ulcer.

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

Table 4.jpg
Table 3.jpg
Table 1.jpg
Table 2.jpg